CSL Reports Top-line Data from the P-III (AEGIS-II) Study of CSL112 for Acute Myocardial Infarction (AMI)
Shots:
- CSL has reported top-line results from the P-III (AEGIS-II) study assessing the safety and efficacy of CSL112 vs PBO to reduce recurrent cardiovascular events at a duration of 90 days in patients (n=18,200) following AMI
- The results revealed that the trial was unable to meet the 1EP of major adverse cardiovascular events (MACE) reduction at 90 days due to which no near-term regulatory filing is anticipated. Further analysis is in progress
- CSL112 [Apolipoprotein A-I (Human)], a cholesterol efflux enhancer, is developed with a novel formulation of human plasma-derived Apolipoprotein A-I (apoA-I) that is the primary functional component of high-density lipoproteins (HDL)
Ref: CSL | Image: CSL
Related News:- CSL & Arcturus Therapeutics Receives MHLW Approval for ARCT-154 to Treat COVID in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
